One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?
Andrew J.VickersaGiorgioRussobHansLiljacChristopherEvansdJack A.SchalkeneEricKleinfScottEggenerg
The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials
RezaSari MotlaghabMohammadAbufarajcdKeiichiroMoriaeAbdulmajeedAydhafPawelRajwaagSatoshiKatayamaahNico C.GrossmannaiEkaterinaLaukhtinaajHadiMostafaiakBenjaminPradereaFahadQuhalalPierre I.KarakiewiczmDmitry V.EnikeevjShahrokh F.Shariatacjnopq
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer
DennieMeijerabWietse S.C.EppingacRoos M.MohedeaBen G.L.VannestedPhilipMeijneneOtto W.M.MeijereLaurien A.DanielseRoderick C.N.van den BerghfAnne P.LontgRosemarijn H.EttemaaFrederik H.K.OudshoornhPim J.van LeeuweniHenk G.van der PoeliMaarten L.DonswijkjDaniela E.Oprea-LagerbEva E.SchaakekAndré N.Visai
Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review
Maria MonicaRattiab1GiorgioGandagliac1EugeniaAllevaaLucaLeardinibElena SilviaSiscabAlexandraDereviankobFedericaFurnaribSerenaMazzoleni FerracinibKatharinaBeyerdCharlotteMossdFrancescoPellegrinocGabrieleSorcecFrancescoBarlettacSimoneScudericMuhammad ImranOmareStevenMacLennanePaula R.WilliamsonfJihongZongg…AlbertoBrigantic2
Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
EstefaniaLabancaabcJunYangabPeter D.A.ShepherdabXinhaiWanabMichael W.StarbuckabLeah D.GuerraabNicolasAnselminoabJuan A.BizzottodeJiabinDongabArul M.ChinnaiyanfgMurali K.RavoorihVikasKundrahiBradley M.BroomjPaul G.CornabPatriciaTroncosokGeraldineGuerondeChristopher J.LogothethisabNora M.Navoneab
Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study
MichaelAhdoota†Amir H.Lebastchia†LoriLongbAndrew R.WilburaPatrick T.GomellaaSherifMehralivandacMichael A.DaneshvaraNitin K.YerramaLuke P.O’ConnoraAlex Z.WangaSandeepGurramaJonathanBloomaM. MinhajSiddiquidW. MarstonLinehanaMariaMerinoePeter L.ChoykecPaulPinskyfHowardParnesf…Peter A.Pintoa
Expanding Active Surveillance Inclusion Criteria: A Novel Nomogram Including Preoperative Clinical Parameters and Magnetic Resonance Imaging Findings
AnnaLantzabc†Ugo GiovanniFalagarioad†ParitaRatnaniaIvanJamborefZachDoveyaAlbertoMartinigSaraLewiseDaraLundonaSujitNairaDeronPhillipaKennethHaineshLuigiCormiodiGiuseppeCarrieridNatashaKryprianouaAshTewaria
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
Cyrill A.RentschaGeorge N.ThalmannbIlariaLuccacMaciejKwiatkowskideGrégory J.WirthfRäto T.StrebelgDanielEngelerhAugustoPedrazziniiClemensHüttenbrinkjWolfgangSchultze-SeemannkRaimundTorpailLukasBubendorfmAndreasWickin†BeatRotho‡PietBosshardp‡HeikePüschelaDaniel T.BollqLukasHefermehlr…StefanieHayozv
Immune Contexture and Differentiation Features Predict Outcome in Bladder Cancer
AnnTaberab†FrederikPripab†PhilippeLamyaMadsAgerbækcJørgen BjerggaardJensenbdTorbenSteinicheeLarsDyrskjøtab
Establishing a Foundation for Studying the Immune Contexture Across the Spectrum of Bladder Cancer
Morgan E.RobertsAlbertoContreras-SanzPeter C.Black
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
RaquibulHannanabMichaelChristensenaHansHammersbcAlanaChristiebBrendanPaulmanaDandanLinaAurelieGarantabWaddahArafatbcKevinCourtneybcIsaacBowmanbcSuzanneColebcDavidSheraChulAhncHakChoyaRobertTimmermanabJamesBrugarolasbc
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial
Brian I.RiniaMichael B.AtkinsbElizabeth R.PlimackcDenisSoulièresdRaymond S.McDermotteJensBedkefSophieTartasgBorisAlekseevhBohuslavMelichariYaroslavShparykjChihiroKondohkPrzemyslawLangiewiczlLori A.WoodmHansHammersnCynthia G.SilberoBarbaraHaberoErinJensenoMeiChenoThomasPowlesp
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group
AxelGerdtssonabAnnaThoracAnnaGrenabo BergdahldeBjarteAlmåsfUlfHåkanssongMagnusTörnblomhiHelene F.S.NegaardjIngridGlimeliuskDagHalvorsenl�saKarlsdóttirmHegeSagstuen HaugnesnoKristineEngen AndreassenjSigneMelsen LarsenpGöranHolmbergeRolfWahlqvistpTorgrimTandstadqrGabriellaCohn-CedermarkstOlofStåhluvAndersKjellmanac
New Landmarks Towards Reducing the Treatment Burden for Patients with a Postchemotherapy Residual Retroperitoneal Mass from Nonseminomatous Germ-cell Testicular Tumors
NicolaNicolaiaSebastianoNazzaniab
Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy
Benjamin W.Fischer-ValuckaSagar A.PatelaRandall J.BrennemanbJohnChristodouleascPaulSargosdEricKimeAaronWeissfBruceHershatteraYuan J.RaogJoelPicushBruceRothhVivekArorahRubenCarmonaiMelissaReimershMohamed S.ZaghlouljHiramGaybJeff M.MichalskibBrian C.Baumannb
Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non–muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience
RobertoContieriab†MarcoPaciottiab†GiovanniLughezzaniabNicolò M.BuffiabNicolaFregoabPietroDianaabVittorioFasuloabAlbertoSaitabPaoloCasalebMassimoLazzeribGiorgioGuazzoniabRodolfoHurleb
Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines
UmbertoCapitanioabRiccardoAutorinocMarcoBandiniabAlbertoBrigantiabLiangChengdMatthew R.CooperbergeFedericoDehòfAndreaGallinaabLaurenceKlotzgBrianLanehiRodolfoMontironijAndreaSaloniaabChristianStiefkBertrandTomballFrancescoMontorsiab
Incidental Prostate Cancer: A Real Need for Expansion in Guidelines?
NicolasMottetaOlivierRouvierebTheodorus H.van der Kwastc
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited
UmbertoCapitanioabRiccardoAutorinocMarcoBandiniabAlbertoBrigantiabLiangChengdMatthew R.CooperbergeFedericoDehòfAndreaGallinagLaurenceKlotzhBrian R.LaneijRodolfoMontironikAndreaSaloniaabChristianStieflBertrandTombalmFrancescoMontorsiab
Re: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021;4:927–42: Considerations for Interpreting Data Presented in Systematic Reviews and Network Meta-analyses of Urinary Biomarker Tests
Cho-HanChiangaCho-HsienChiangbCho-HungChiangc
